Literature DB >> 24347041

Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression.

David Barras1, Girieca Lorusso, Benoît Lhermitte, David Viertl, Curzio Rüegg, Christian Widmann.   

Abstract

The p120 RasGAP protein negatively regulates Ras via its GAP domain. RasGAP carries several other domains that modulate several signaling molecules such as Rho. RasGAP is also a caspase-3 substrate. One of the caspase-3-generated RasGAP fragments, corresponding to amino acids 158-455 and called fragment N2, was previously reported to specifically sensitize cancer cells to death induced by various anticancer agents. Here, we show that fragment N2 inhibits migration in vitro and that it impairs metastatic progression of breast cancer to the lung. Hence, stress-activated caspase-3 might contribute to the suppression of metastasis through the generation of fragment N2. These results indicate that the activity borne by fragment N2 has a potential therapeutic relevance to counteract the metastatic process.
© 2013 UICC.

Entities:  

Keywords:  RasGAP; fragment N2; metastasis; migration; peptide

Mesh:

Substances:

Year:  2014        PMID: 24347041     DOI: 10.1002/ijc.28674

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  RasGAP Shields Akt from Deactivating Phosphatases in Fibroblast Growth Factor Signaling but Loses This Ability Once Cleaved by Caspase-3.

Authors:  Katia Cailliau; Arlette Lescuyer; Anne-Françoise Burnol; Álvaro Cuesta-Marbán; Christian Widmann; Edith Browaeys-Poly
Journal:  J Biol Chem       Date:  2015-06-24       Impact factor: 5.157

2.  Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore.

Authors:  Gianvito Grasso; Mathieu Heulot; Nadja Chevalier; Evgeniya Trofimenko; Marco A Deriu; Gilles Dubuis; Yoan Arribat; Marc Serulla; Sebastien Michel; Gil Vantomme; Florine Ory; Linh Chi Dam; Julien Puyal; Francesca Amati; Anita Lüthi; Andrea Danani; Christian Widmann
Journal:  Elife       Date:  2021-10-29       Impact factor: 8.140

Review 3.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

4.  Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer.

Authors:  Hyojin Kim; Kyung-Hun Lee; In Ae Park; Yul Ri Chung; Seock-Ah Im; Dong-Young Noh; Wonshik Han; Hyeong-Gon Moon; Yoon Yang Jung; Han Suk Ryu
Journal:  Virchows Arch       Date:  2015-08-18       Impact factor: 4.064

5.  A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide.

Authors:  David Barras; Nadja Chevalier; Vincent Zoete; Rosemary Dempsey; Karine Lapouge; Monilola A Olayioye; Olivier Michielin; Christian Widmann
Journal:  J Biol Chem       Date:  2014-07-09       Impact factor: 5.157

6.  Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers.

Authors:  Nadja Chevalier; Nicole Gross; Christian Widmann
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

7.  The Anticancer Peptide TAT-RasGAP317-326 Exerts Broad Antimicrobial Activity.

Authors:  Mathieu Heulot; Nicolas Jacquier; Sébastien Aeby; Didier Le Roy; Thierry Roger; Evgeniya Trofimenko; David Barras; Gilbert Greub; Christian Widmann
Journal:  Front Microbiol       Date:  2017-06-07       Impact factor: 5.640

8.  Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Authors:  Malgorzata Banys-Paluchowski; Tanja Fehm; Wolfgang Janni; Bahriye Aktas; Peter A Fasching; Sabine Kasimir-Bauer; Karin Milde-Langosch; Klaus Pantel; Brigitte Rack; Sabine Riethdorf; Erich-Franz Solomayer; Isabell Witzel; Volkmar Müller
Journal:  BMC Cancer       Date:  2018-05-08       Impact factor: 4.430

9.  The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.

Authors:  Mathieu Heulot; Nadja Chevalier; Julien Puyal; Christiane Margue; Sébastien Michel; Stephanie Kreis; Dagmar Kulms; David Barras; Aimable Nahimana; Christian Widmann
Journal:  Oncotarget       Date:  2016-09-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.